Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitor
Pharma
EyePoint's Duravyu bounces back with promising DME data
EyePoint revitalized its star asset Duravyu with strong diabetic macular edema data, opening a path forward for other potential retinal indications.
Fraiser Kansteiner
Oct 28, 2024 1:11pm
Clearside's CLS-AX excels in phase 2b trial, set for phase 3
Oct 9, 2024 11:47am
Takeda circles Ascentage's Scemblix challenger for up to $1.3B
Jun 14, 2024 11:30am
Boehringer Ingelheim preps for 2 upcoming oncology launches
Jun 10, 2024 8:20am
Merck and Eisai call it quits on drug combo trial in melanoma
Apr 7, 2023 9:43am
Novartis wins CML nod for new Gleevec follow-on Scemblix
Nov 1, 2021 6:51am
